Market News
- AmplifyBio and Xcell enter TCR T-cell therapy manufacturing dealby Vishnu Priyan (Pharmaceutical Technology) on May 21, 2024
AmplifyBio and Xcell Biosciences have announced a strategic collaboration to manufacture engineered T-cell receptor (TCR) therapies.
- Pharma Pulse 5/21/24: Musk’s Neuralink Gets FDA Green Light for Second Patient, Uber Caregiver to Support Caregivers Across the US & moreby OncLive articles on May 21, 2024
The latest news for pharma industry insiders.
- US Pharma and Biotech Summit 2024: Redefining the Patient Relationshipby OncLive articles on May 21, 2024
Experts discuss how new innovations are changing the relationship the industry has with patients.
- US Pharma and Biotech Summit 2024: Solving Drug Pricingby OncLive articles on May 21, 2024
Experts discuss how attempts to solve the drug pricing problem in the US are working.
- FDA grants approval for two Eylea biosimilars for eye conditionsby Vishnu Priyan (Pharmaceutical Technology) on May 21, 2024
The US FDA has approved Yesafili and Opuviz, two interchangeable biosimilars to Eylea, for macular degeneration and other eye conditions.
- AstraZeneca to establish $1.5bn ADC production site in Singaporeby Vishnu Priyan (Pharmaceutical Technology) on May 21, 2024
AstraZeneca is set to invest $1.5bn in a new manufacturing facility in Singapore dedicated to the production of antibody drug conjugates.
- Pheon rides wave of ADC interest with $120M financingby Gwendolyn Wu (BioPharma Dive – Latest News) on May 21, 2024
CEO Cyrus Mozayeni said the company is taking a different approach than other developers of antibody-drug conjugates, though it’s keeping details close.
- Q1 2024 update: M&A activity in pharmaceutical in Swedenby kgi-admin (Pharmaceutical Technology) on May 21, 2024
In Sweden pharmaceutical industry, there were 6 M&A deals announced in Q1 2024, worth a total value of $2.3m, according to GlobalData’s Deals Database.
- How future of work private equity performed in the pharmaceutical industry in Q1 2024by kgi-admin (Pharmaceutical Technology) on May 21, 2024
In the global pharmaceutical industry, there were 3 private equity deals announced in Q1 2024, worth a total value of $345m, according to GlobalData’s Deals Database.
- Q1 2024 update: personalization related M&A activity in the pharmaceutical industryby kgi-admin (Pharmaceutical Technology) on May 21, 2024
In the global pharmaceutical industry, there were 2 M&A deals announced in Q1 2024, worth a total value of $418m, according to GlobalData’s Deals Database.
- Q1 2024 update: individualism & expression related M&A activity in the pharmaceutical industryby kgi-admin (Pharmaceutical Technology) on May 21, 2024
In the global pharmaceutical industry, there were 2 M&A deals announced in Q1 2024, worth a total value of $418m, according to GlobalData’s Deals Database.
- US Pharma and Biotech Summit 2024: The 2024 Presidential Election and the Pharma Industryby OncLive articles on May 20, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Robert Zirkelback, Chief Public Affairs Officer, Head of Strategic Initiatives, PhRMA discusses the upcoming United States presidential election and the potential impact that it could have […]
- Forbion-backed biotech Progentos debuts with $65M for MS drugby Jacob Bell (BioPharma Dive – Latest News) on May 20, 2024
Progentos says the money will go toward expanding its pipeline and pushing an experimental treatment for multiple sclerosis through “proof of concept” testing.
- BIO to restructure, lay off staff in shakeup of lobbying groupby Ned Pagliarulo (BioPharma Dive – Latest News) on May 20, 2024
Thirty employees will leave as part of the reorganization, which the group said is meant to bring “stronger focus and greater impact” to its work.
- Final report says UK infected blood scandal “should have been avoided” by Jenna Philpott (Pharmaceutical Technology) on May 20, 2024
Nearly 30,000 people, including children in clinical trials, were infected with hepatitis C and HIV from contaminated blood products in the 1970s and 1980s.
- Dyne shares jump on trial data for muscle disease drugsby Ned Pagliarulo (BioPharma Dive – Latest News) on May 20, 2024
Updated study results for the biotech’s medicines for myotonic dystrophy Type 1 and Duchenne muscular dystrophy appeared to impress analysts and investors on Wall Street.
- European Commission, in ‘unprecedented’ move, declines to revoke approval of PTC Duchenne drugby Ben Fidler (BioPharma Dive – Latest News) on May 20, 2024
Rather than endorse the recommendation of the EMA, the commission called for a new review for Translarna that considers “the totality of the evidence” compiled to date.
- Amgen and AstraZeneca ponder label expansion for Tezspire in COPDby Phalguni Deswal (Pharmaceutical Technology) on May 20, 2024
The companies plan to start Phase III trials for Tezspire in COPD despite missing the primary endpoint in the Phase IIb study.
- UK clinical trials industry tackles recent changes in the sectorby Akosua Mireku (Pharmaceutical Technology) on May 20, 2024
The Annual Outsourcing in Clinical Trials conference will gather pharma experts to discuss the UK clinical trial landscape.
- Coya Therapeutics Receives $5 Million Investment from the Alzheimer’s Drug Discovery Foundationby OncLive articles on May 20, 2024
Investment from the Alzheimer’s Drug Discovery Foundation (ADDF) aims to support the development of Coya 302, a therapeutic candidate for the treatment of frontotemporal dementia (FTD).